Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment

Abstract

A new allergenic preparation consisting of peptic fragments of short ragweed has been tested for its clinical effectiveness. Such enzymatically derived fragments have been shown in prior murine studies to retain the T epitopes of the original allergen but to have a severe reduction in the number of B epitopes. Three groups of ragweed hay fever patients were placed on pre‐seasonal immunotherapy. One group received a conventional ragweed preparation that had been enriched for antigen E (Amh a I), designated as Pool 2. The second group was given fragments of Pool 2 (fSRW) prepared by peptic digestion and the third group was injected with histainine as a placebo. Groups treated with the fSRW and Pool 2 had significantly reduced symptom‐medication scores compared with the placebo‐treatment group. However, fSRW‐treated patients fared significantly better than Pool 2 patients (P<0.02). FSRW injections caused a significant rise in preseasonal specific IgG antibodies as well as suppression of the seasonal anamnestic specific IgE increase. Similar, but not quite as marked changes occurred with Pool 2 treatment, f SRW was well tolerated and non‐toxic. Thus, allergen modification by enzymatic degradation, as demonstrated here, appears to be a promising new approach for allergen immunotherapy.